Chronic Cavitary and Fibrosing Pulmonary and Pleural Aspergillosis: Case Series, Proposed Nomenclature Change, and Review

Clinical Infectious Diseases

Volumn 37, Issue SUPPL. 3, 2003, Pages

  Denning, David W ^a,c   Riniotis, Kostantinos ^a   Dobrashian, Richard ^b   Sambatakou, Helen ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^c WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; GAMMA INTERFERON; IMMUNOGLOBULIN E; ITRACONAZOLE; PRECIPITIN;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COUGHING; DISEASE DURATION; DYSPNEA; FATIGUE; FEMALE; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; LUNG ASPERGILLOSIS; LUNG BIOPSY; LUNG CAVITY; LUNG FIBROSIS; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; THORAX PAIN; TREATMENT OUTCOME; WEIGHT REDUCTION; ASPERGILLOSIS; FIBROSIS; IMMUNOLOGY; LUNG MYCOSIS; MIDDLE AGED; PLEURA DISEASE; SEROLOGY;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; FEMALE; FIBROSIS; HUMANS; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; PLEURAL DISEASES; SEROLOGIC TESTS; TREATMENT OUTCOME;

EID: 0141887305     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/376526     Document Type: Article

References (45)

1. Denning DW. Aspergillus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 5th ed. Philadelphia: W. B. Saunders, 2000:2674-82.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-805.
3. Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 654-62.
4. Segal BH, DeCarlo ES, Kwon Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998; 77:345-54.
5. Belcher JR, Plummer NS. Surgery in bronchopulmonary aspergillosis. Br J Dis Chest 1960; 54:335-41.
6. Giron J, Sans N, Poey C, Fajadet P, Fourcade D, Senac JP, Railhac JJ. CT-guided percutaneous treatment of inoperable pulmonary aspergillomas: a study of 42 cases. J Radiol 1998; 79:139-45.
7. Crosdale D, Poulton K, Ollier W, Thomson W, Denning DW. Mannose binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J Infect Dis 2001; 184:653-6.
8. Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001; 7(Suppl 2):25-31.
9. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis; review of 2,121 published cases. Rev Infect Dis 1990; 12:1147-201.
10. Gefter WB, Weingrad TR, Epstein DM, Ochs RH, Miller WT. "Semi-invasive" pulmonary aspergillosis: a new look at the spectrum of Aspergillus infections of the lung. Radiology 1981; 140:313-21.
11. Binder RE, Faling LJ, Pugatch RD, Mahasaen C, Snider GL. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) 1982; 61:109-24.
12. Madan T, Kishore U, Singh M, et al. Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis. Infect Immun 2001; 69:2728-31.
13. Madan T, Kishore U, Singh M, et al. Surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens. J Clin Invest 2001; 107:467-75.
14. Rubin H, Furcolow ML, Yates JL, Brasher CA. The course and prognosis of histoplasmosis. Am J Med 1959; 27:278-88.
15. Winn WA. A long term study of 300 patients with cavitary-abscess lesions of the lung of coccidioidal origin. An analytical study with special reference to treatment. Dis Chest 1968; 54 (Suppl 1):268-72.
16. Salkin D, Hubbert M. Review of 706 cases of pulmonary cavities in the coccidioidomycosis VA-AF Cooperative Study [abstract 12]. In: Proceedings of the 23rd annual Coccidioidomycosis Study Group meeting (Beverly Hills). California Thoracic Society, 1978.
17. Palmer LB, Greenberg HE, Schiff MJ. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax 1991; 46:15-20.
18. Rodrigues J, Niederman MS, Fein AM, Pai PB. Nonresolving pneumonia in steroid treated patients with obstructive lung disease. Am J Med 1992; 93:29-34.
19. Caras WE, Pluss JL. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin Proc 1996; 71: 25-30.
20. Rello J, Esandi ME, Mariscal D, Gallego M, Domingo C, Valles J. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review. Clin Infect Dis 1998; 26:1473-5.
21. Thommi G, Bell G, Liu J, Nugent K. Spectrum of invasive pulmonary aspergillosis in immunocompetent patients with chronic obstructive pulmonary disease. South Med J 1991; 84:828-31.
22. Pittet D, Huguenin T, Dharan S, et al. Unusual cause of lethal pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154:541-4.
23. Conesa D, Rello J, Valles J, Mariscal D, Ferreres JC. Invasive aspergillosis: a life threatening complication of short term steroid treatment. Ann Pharmacother 1995; 29:1235-7.
24. O'Brien AAJ, Moore DP, Keogh JAB. Pulmonary berylliosis on corticosteroid therapy with cavitating lung lesions and aspergilomata - report on a fatal case. Postgrad Med J 1987; 63:797-9.
25. Waldhorn RE, Tsou E, Kerwin DM. Invasive pulmonary aspergillosis associated with aspergilloma and sarcoidosis. South Med J 1983; 76: 251-3.
26. Israel HL, Ostrow A. Sarcoidosis and aspergilloma. Am J Med 1969; 47:243-50.
27. Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1997; 112:541-8.
28. Yousem SA. The histological spectrum of chronic necrotizing forms of pulmonary aspergillosis. Hum Pathol 1997; 28:650-6.
29. Casadevall A, Pirofski LA. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect Immun 1999; 67: 3703-13.
30. Cenci E, Perito S, Enssle KH, et al. Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun 1997; 65:564-70.
31. Cenci E, Menacci A, Del Sero G, et al. Interleukin-4 causes susceptibility to invasive aspergillosis through suppression of protective type 1 responses. J Infect Dis 1999; 180:1957-68.
32. Clemons KV, Grunig G, Sobel RA, Mirels LF, Rennick DM, Stevens DA. Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis. Clin Exp Immunol 2000; 122:186-91.
33. Louie A, Baltch AL, Franke MA, Smith RP, Gordon MA. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J Antimicrob Chemother 1994; 34:975-87.
34. Rogers PD, Stiles JK, Chapman SW, Cleary JD. Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1. J Infect Dis 2000; 182:1280-3.
35. Kim JH, Ahn YK. The effects of itraconazole on the immune responses in ICR mice. J Toxicol Sci 1994; 19:7-15.
36. Hafeez I, Muers MF, Murphy SA, Evans EG, Barton RC, McWhinney P. Non-tuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis. Thorax 2000; 55:717-9.
37. Gerstl B, Weidman WH, Newman AV. Pulmonary aspergillosis. Report on two cases. Ann Intern Med 1948; 28:662-71.
38. Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax 1983; 38:572-8.
39. Battaglini JW, Murray GF, Keagy BA, Starek PJ, Wilcox BR. Surgical management of symptomatic pulmonary aspergilloma. Ann Thorac Surg 1985; 39:512-6.
40. Babatasi G, Massetti M, Chapelier A, et al. Surgical treatment of pulmonary aspergilloma: current outcome. J Thorac Cardiovasc Surg 2000; 119:906-12.
41. Daly RC, Pairolero PC, Piehler JM, Trastek VF, Payne WS, Bernatz PE. Pulmonary aspergilloma: results of surgical treatment. J Thorac Cardiovasc Surg 1986; 92:981-8.
42. Massard G, Roeslin N, Wihlm JM, Dumont P, Witz JP, Morand G. Pleuropulmonary aspergilloma: clinical spectrum and surgical treatment. Ann Thorac Surg 1992; 54:1159-64.
43. El-Oakley R, Petrou M, Goldstraw P. Indications and outcome of surgery for pulmonary aspergilloma. Thorax 1997; 52:813-5.
44. Chen JC, Chang YL, Luh SP, Lee JM, Lee YC. Surgical treatment for pulmonary aspergilloma: a 28 year experience. Thorax 1997; 52:810-3.
45. Dupont B, Denning DW, Lode H, Yonren S, Troke P, Sarantis N. UK 109,496 (Voriconazole), a novel, wide spectrum triazole derivative for the treatment of fungal infections. Clinical efficacy in chronic invasive aspergillosis [abstract F-81]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:125.